COMPANY PROFILE // THE 014 REPORT
Aclaris Therapeutics, Inc.
ACRS (Nasdaq)
Assembled from 4 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberLEI 5493000B2LQ9QTW1DF52 registration status is LAPSED (last update 2026-10-25): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
Aclaris Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Wayne, PA; listed as ACRS (Nasdaq).[source] It reported revenue of $7.8 million for the fiscal year ended 2025-12-31.[source] It has filed 62 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: LEI 5493000B2LQ9QTW1DF52 registration status is LAPSED (last update 2026-10-25).[source]
- red0
- amber1
- info1
- RA CAPITAL MANAGEMENT, L.P.$67.3M
- BML Capital Management, LLC$63.3M
- BlackRock, Inc.$53.1M
- Deep Track Capital, LP$49.4M
- Vivo Capital, LLC$35.4M
- VANGUARD CAPITAL MANAGEMENT LLC$30.8M
- Frazier Life Sciences Management, L.P.$26.1M
- Rock Springs Capital Management LP$22.9M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Balthaser Kevin · Chief Financial Officer (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Davis Hugh M. · President and COO (Director,Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- Hall Jesse Wayne · Chief Medical Officer (Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- Kolbeck Roland Wilhelm · Chief Scientific Officer (Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- Loerop James · Chief Business Officer (Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- Walker Neal · CEO (Director,Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- GOWEN MAXINE · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Humphries William D. · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- MILANO VINCENT · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Mehra Anand · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- Molineaux Christopher P. · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
- SCHIFF ANDREW N · Director · latest Form 4 2025-06-09 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Mark Ballantyne Mark Ballantyne Cooley LLP · Exhibit 5.1 legal opinion, S-3ASR filed 2026-08-06
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001557746 | source |
| LEI | 5493000B2LQ9QTW1DF52 | source |
| EIN | 46-0571712 | source |
| Business address (SEC) | 701 LEE ROAD, WAYNE, PA, 19087 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2026-10-25 · in -26 days · LEI next renewal (5493000B2LQ9QTW1DF52)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Aldeyra Therapeutics, Inc. · Walker Neal
- Passage BIO, Inc. · GOWEN MAXINE
- BIOCRYST PHARMACEUTICALS INC · MILANO VINCENT
- Monte Rosa Therapeutics, Inc. · SCHIFF ANDREW N
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-27 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-10-27 filing 424B5 · SEC EDGAR
- 2026-10-27 filing 8-K items 2.02,7.01,8.01,9.01 · SEC EDGAR
- 2026-08-06 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-08-06 filing S-3ASR · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-04 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-28 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-04-23 filing ARS · SEC EDGAR
- 2026-04-23 filing DEFA14A · SEC EDGAR
- 2026-04-23 filing Proxy statement · SEC EDGAR
- 2026-03-11 filing 8-K items 7.01 · SEC EDGAR
- 2026-03-10 filing 8-K items 7.01 · SEC EDGAR
- 2026-02-26 filing Annual report (10-K) · SEC EDGAR
- 2026-02-26 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-12 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-01-06 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-01-05 insider First Form 3/4/5 on record for Balthaser Kevin (Chief Financial Officer) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Loerop James (Chief Business Officer) · SEC Forms 3/4/5
- 2025-12-04 insider First Form 3/4/5 on record for Davis Hugh M. (President and COO) · SEC Forms 3/4/5
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-10-14 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2025-08-07 filing Quarterly report (10-Q) · SEC EDGAR
121 earlier entries
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-08-05 insider First Form 3/4/5 on record for Kolbeck Roland Wilhelm (Chief Scientific Officer)
- 2025-07-29 filing 8-K items 7.01,8.01,9.01
- 2025-06-30 filing 8-K items 7.01,9.01
- 2025-06-09 insider First Form 3/4/5 on record for GOWEN MAXINE (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Humphries William D. (Director)
- 2025-06-09 insider First Form 3/4/5 on record for MILANO VINCENT (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Mehra Anand (Director)
- 2025-06-09 insider First Form 3/4/5 on record for Molineaux Christopher P. (Director)
- 2025-06-09 insider First Form 3/4/5 on record for SCHIFF ANDREW N (Director)
- 2025-06-05 filing S-8
- 2025-06-05 officer change 8-K items 5.02,5.03,5.07,9.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,7.01,9.01
- 2025-05-05 insider First Form 3/4/5 on record for Hall Jesse Wayne (Chief Medical Officer)
- 2025-04-24 filing ARS
- 2025-04-24 filing DEFA14A
- 2025-04-24 filing Proxy statement
- 2025-04-14 filing PRE 14A
- 2025-04-03 insider First Form 3/4/5 on record for Walker Neal (CEO)
- 2025-03-07 filing EFFECT
- 2025-03-05 filing CORRESP
- 2025-03-04 filing UPLOAD
- 2025-02-27 filing S-3
- 2025-02-27 filing Annual report (10-K)
- 2025-02-27 filing 8-K items 2.02,9.01
- 2025-01-13 filing 8-K items 7.01,9.01
- 2024-12-31 filing EFFECT
- 2024-12-31 filing 424B3
- 2024-12-27 filing CORRESP
- 2024-12-26 filing UPLOAD
- 2024-12-19 filing S-3
- 2024-12-04 filing D
- 2024-11-27 filing S-8
- 2024-11-18 officer change 8-K items 1.01,3.02,5.02,7.01,8.01,9.01
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02,9.01
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-07 filing 8-K items 2.02,9.01
- 2024-07-16 filing 8-K items 1.01,7.01,9.01
- 2024-06-07 filing 8-K items 5.07
- 2024-05-07 filing Quarterly report (10-Q)
- 2024-05-07 filing 8-K items 2.02,7.01,9.01
- 2024-05-07 filing S-8
- 2024-04-25 filing ARS
- 2024-04-25 filing DEFA14A
- 2024-04-25 filing Proxy statement
- 2024-03-19 officer change 8-K items 5.02
- 2024-02-27 filing Annual report (10-K)
- 2024-02-27 filing 8-K items 2.02,9.01
- 2024-02-05 officer change 8-K/A items 5.02
- 2024-02-05 officer change 8-K items 5.02
- 2024-01-19 officer change 8-K items 2.02,5.02,9.01
- 2023-12-19 filing 8-K items 2.05,7.01,9.01
- 2023-11-13 filing 8-K items 7.01,8.01,9.01
- 2023-11-06 filing Quarterly report (10-Q)
- 2023-11-06 filing 8-K items 2.02,9.01
- 2023-10-23 filing 144
- 2023-09-18 filing 8-K items 7.01,9.01
- 2023-08-21 filing 144
- 2023-08-07 filing Quarterly report (10-Q)
- 2023-08-07 filing 8-K items 2.02,9.01
- 2023-06-20 filing 144
- 2023-06-12 officer change 8-K items 5.02,9.01
- 2023-06-02 filing 8-K items 5.07
- 2023-06-01 filing 8-K items 1.01,9.01
- 2023-05-08 filing S-8
- 2023-05-08 filing Quarterly report (10-Q)
- 2023-05-08 filing 8-K items 2.02,7.01,9.01
- 2023-04-20 filing DEFA14A
- 2023-04-20 filing Proxy statement
- 2023-04-20 filing ARS
- 2023-04-14 filing 8-K items 7.01,9.01
- 2023-04-10 filing PRE 14A
- 2023-03-31 filing 8-K items 7.01
- 2023-03-27 officer change 8-K items 5.02,9.01
- 2023-03-06 filing 8-K items 8.01,9.01
- 2023-02-23 filing 8-K items 1.01,1.02,9.01
- 2023-02-23 filing 424B5
- 2023-02-23 filing Annual report (10-K)
- 2023-02-23 filing 8-K items 2.02,9.01
- 2023-01-09 filing 8-K items 7.01,9.01
- 2023-01-06 officer change 8-K items 5.02
- 2022-12-13 officer change 8-K items 5.02
- 2022-11-22 officer change 8-K items 5.02
- 2022-11-08 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,7.01,9.01
- 2022-08-03 filing Quarterly report (10-Q)
- 2022-08-03 filing 8-K items 2.02,9.01
- 2022-08-01 officer change 8-K items 5.02,9.01
- 2022-06-03 filing 8-K items 5.07
- 2022-05-10 filing S-8
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-04-21 filing DEFA14A
- 2022-04-21 filing Proxy statement
- 2022-04-14 filing 8-K items 7.01
- 2022-02-24 filing Annual report (10-K)
- 2022-02-24 filing 8-K items 2.02,9.01
- 2022-01-14 officer change 8-K items 5.02,9.01
- 2021-12-07 filing 8-K items 7.01,9.01
- 2021-11-02 filing Quarterly report (10-Q)
- 2021-11-02 officer change 8-K items 2.02,5.02,9.01
- 2021-08-27 filing 8-K items 7.01,9.01
- 2021-08-05 filing Quarterly report (10-Q)
- 2021-08-05 filing 8-K items 2.02,9.01
- 2021-07-26 filing 8-K items 1.02
- 2021-06-11 filing 8-K items 1.01,8.01,9.01
- 2021-06-10 filing 424B5
- 2021-06-08 filing 424B5
- 2021-06-08 filing 8-K items 7.01,8.01,9.01
- 2021-06-03 filing 8-K items 5.07
- 2021-05-20 filing S-3ASR
- 2021-05-20 filing 8-K items 1.01,9.01
- 2021-05-07 filing S-8
- 2021-05-07 filing Quarterly report (10-Q)
- 2021-05-07 filing 8-K items 2.02,9.01
- 2021-04-22 filing DEFA14A
- 2021-04-22 filing Proxy statement
- 2021-02-25 filing Annual report (10-K)
- 2021-02-25 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-27 (within 30 days) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-10-27 (within 30 days) 424B5 filed
- 2026-10-27 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-13 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:ACRS The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1557746 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | ACRS / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 5493000B2LQ9QTW1DF52 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 5493000B2LQ9QTW1DF52) | GLEIF |
| EIN | 460571712 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001557746 | SEC EDGAR / IRS |
| CUSIP | 00461U105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001557746 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $7,826,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-19 22:34 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$64,923,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 22:34 UTC | Report an error |
| Total assets (at 2025-12-31) | $160,460,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-19 22:34 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $103,082,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 22:34 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $19,960,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-19 22:34 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
| Business address | 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-19 22:34 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$47,113,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 22:34 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $111,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-19 22:34 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $2,116,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 22:34 UTC | Report an error |
| Form D total offering amount (D filed 2024-12-04) | $79,999,999 | 2024-12-04 | D | as filed | 2026-11-19 22:34 UTC | Report an error |
| Form D total amount sold (D filed 2024-12-04) | $79,999,999 | 2024-12-04 | D | as filed | 2026-11-19 22:34 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2024-12-04 | D | as filed | 2026-11-19 22:34 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2024-12-04 | D | as filed | 2026-11-19 22:34 UTC | Report an error |
| Form D date of first sale | 2024-11-19 | 2024-12-04 | D | as filed | 2026-11-19 22:34 UTC | Report an error |
| Plan (pension, plan no. 001) | ACLARIS THERAPEUTICS INC 401(K) PLAN: 118 participants, assets $16,165,498 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-19 22:34 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123374
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $1,481,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123374 | 2026-11-19 22:34 UTC | Report an error |
| Net income (loss) | -$18,510,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123374 | 2026-11-19 22:34 UTC | Report an error |
| Cash and cash equivalents | $20,394,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123374 | 2026-11-19 22:34 UTC | Report an error |
| Contract liabilities, current | $3,966,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123374 | 2026-11-19 22:34 UTC | Report an error |
| Contract liabilities, noncurrent | $13,334,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001104659-26-123374 | 2026-11-19 22:34 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-27 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-10-27 Filing 424B5 filed
- 2026-10-27 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-13 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-06 Filing S-3ASR filed
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-04 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-28 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-04-23 Filing ARS filed
- 2026-04-23 Filing DEFA14A filed
- 2026-04-23 Filing DEF 14A filed
- 2026-03-11 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-03-10 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-02-26 Filing 10-K filed
- 2026-02-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-12 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-01-06 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed
2 earlier entries
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2012-10-01 Record plan effective date: ACLARIS THERAPEUTICS INC 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-16 8-K Item 7.01, Regulation FD Disclosure
On November 16, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing top line results from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (the “Top Line Results”). A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. On November 16, 2026, the Registrant also issued a press release announcing the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138), an investigational oral inhibitor of interleukin-2-inducible T cell kinase and… the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-11-16 8-K Item 8.01, Other Events
Top Line Results The Top Line Results announced were as follows: The Phase 2 trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 or secondary endpoints. Pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in the trial. ALPHA Trial The Registrant announced that it expects top line results from the oral erosive lichen planus cohort of the ALPHA Trial in the second half of 2027. Other Announcements The Registrant also announced the following: The Registrant has completed… the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended… the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-10-27 8-K Item 1.01
Entry into a Material Definitive Agreement. On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters (the “Underwriters”) listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share (“Common Stock”) and pre-funded warrants to purchase 6,500,000 shares of Common Stock (the “Pre-Funded Warrants”), in an underwritten offering pursuant to an effective registration statement on Form S-3 (File No. 333-298084) and a related prospectus and prospectus… the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-10-27 8-K Item 2.02, Results of Operations and Financial Condition
The information disclosed under the heading “Cash, Cash Equivalents and Marketable Securities as of September 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-10-27 8-K Item 7.01, Regulation FD Disclosure
On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) issued a press release announcing primary analysis results from the Phase 1b proof-of-concept (“POC”) trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis (“AD”) and asthma (the “Results”). The Company also announced it would hold a webcast and conference call with slides related to the Results. A copy of the press release and the presentation that will accompany the webcast and conference call are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Item 9.01… the 8-K · retrieved 2026-11-19 22:34 UTC - 2026-10-27 8-K Item 8.01, Other Events
Cash, Cash Equivalents and Marketable Securities as of September 30, 2026 Based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and marketable securities were approximately $204.6 million as of September 30, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and marketable securities as of September 30, 2026 may differ from this amount after it completes its comprehensive accounting procedures for the quarter ended September 30, 2026, and any such differences may be material. Primary Analysis Results The… the 8-K · retrieved 2026-11-19 22:34 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $67,304,808 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 2 | BML Capital Management, LLC | $63,347,750 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 3 | BlackRock, Inc. | $53,095,772 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 4 | Deep Track Capital, LP | $49,435,050 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 5 | Vivo Capital, LLC | $35,414,630 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $30,776,511 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 7 | Frazier Life Sciences Management, L.P. | $26,055,228 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 8 | Rock Springs Capital Management LP | $22,908,514 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $21,535,590 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
| 10 | Decheng Capital LLC | $21,380,783 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:34 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- ACLARIS THERAPEUTICS, INC. · LEI 5493000B2LQ9QTW1DF52 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAclaris Therapeutics, Inc. · exact legal name · sx:ctgov:h635f10899cd9c0cd Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchACLARIS THERAPEUTICS, INC. · exact legal name · sx:elic:ctcred:1444789 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1557746.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001557746. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.